Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
Phase II Chemoradiation Trial Using Gemcitabine in Patients With Locoregional Adenocarcinoma of the Pancreas
Status: Enrolling
Updated:  7/19/2016
The New York Presbyterian Hospital - Cornell Campus
480
mi
from 43215
New York, NY
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
Phase II Chemoradiation Trial Using Gemcitabine in Patients With Locoregional Adenocarcinoma of the Pancreas
Status: Enrolling
Updated: 7/19/2016
The New York Presbyterian Hospital - Cornell Campus
480
mi
from 43215
New York, NY
Click here to add this to my saved trials
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
Phase II Chemoradiation Trial Using Gemcitabine in Patients With Locoregional Adenocarcinoma of the Pancreas
Status: Enrolling
Updated:  7/19/2016
Mount Sinai Medical Center, NY
481
mi
from 43215
New York, NY
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
Phase II Chemoradiation Trial Using Gemcitabine in Patients With Locoregional Adenocarcinoma of the Pancreas
Status: Enrolling
Updated: 7/19/2016
Mount Sinai Medical Center, NY
481
mi
from 43215
New York, NY
Click here to add this to my saved trials
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
Phase II Chemoradiation Trial Using Gemcitabine in Patients With Locoregional Adenocarcinoma of the Pancreas
Status: Enrolling
Updated:  7/19/2016
CCOP - Syracuse Hematology-Oncology Associates of Central New York, P.C.
415
mi
from 43215
Syracuse, NY
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
Phase II Chemoradiation Trial Using Gemcitabine in Patients With Locoregional Adenocarcinoma of the Pancreas
Status: Enrolling
Updated: 7/19/2016
CCOP - Syracuse Hematology-Oncology Associates of Central New York, P.C.
415
mi
from 43215
Syracuse, NY
Click here to add this to my saved trials
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
Phase II Chemoradiation Trial Using Gemcitabine in Patients With Locoregional Adenocarcinoma of the Pancreas
Status: Enrolling
Updated:  7/19/2016
State University of New York Upstate Medical University
417
mi
from 43215
Syracuse, NY
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
Phase II Chemoradiation Trial Using Gemcitabine in Patients With Locoregional Adenocarcinoma of the Pancreas
Status: Enrolling
Updated: 7/19/2016
State University of New York Upstate Medical University
417
mi
from 43215
Syracuse, NY
Click here to add this to my saved trials
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
Phase II Chemoradiation Trial Using Gemcitabine in Patients With Locoregional Adenocarcinoma of the Pancreas
Status: Enrolling
Updated:  7/19/2016
Veterans Affairs Medical Center - Syracuse
415
mi
from 43215
Syracuse, NY
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
Phase II Chemoradiation Trial Using Gemcitabine in Patients With Locoregional Adenocarcinoma of the Pancreas
Status: Enrolling
Updated: 7/19/2016
Veterans Affairs Medical Center - Syracuse
415
mi
from 43215
Syracuse, NY
Click here to add this to my saved trials
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
Phase II Chemoradiation Trial Using Gemcitabine in Patients With Locoregional Adenocarcinoma of the Pancreas
Status: Enrolling
Updated:  7/19/2016
Lineberger Comprehensive Cancer Center, UNC
353
mi
from 43215
Chapel Hill, NC
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
Phase II Chemoradiation Trial Using Gemcitabine in Patients With Locoregional Adenocarcinoma of the Pancreas
Status: Enrolling
Updated: 7/19/2016
Lineberger Comprehensive Cancer Center, UNC
353
mi
from 43215
Chapel Hill, NC
Click here to add this to my saved trials
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
Phase II Chemoradiation Trial Using Gemcitabine in Patients With Locoregional Adenocarcinoma of the Pancreas
Status: Enrolling
Updated:  7/19/2016
Veterans Affairs Medical Center - Durham
351
mi
from 43215
Durham, NC
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
Phase II Chemoradiation Trial Using Gemcitabine in Patients With Locoregional Adenocarcinoma of the Pancreas
Status: Enrolling
Updated: 7/19/2016
Veterans Affairs Medical Center - Durham
351
mi
from 43215
Durham, NC
Click here to add this to my saved trials
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
Phase II Chemoradiation Trial Using Gemcitabine in Patients With Locoregional Adenocarcinoma of the Pancreas
Status: Enrolling
Updated:  7/19/2016
Duke Comprehensive Cancer Center
354
mi
from 43215
Durham, NC
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
Phase II Chemoradiation Trial Using Gemcitabine in Patients With Locoregional Adenocarcinoma of the Pancreas
Status: Enrolling
Updated: 7/19/2016
Duke Comprehensive Cancer Center
354
mi
from 43215
Durham, NC
Click here to add this to my saved trials
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
Phase II Chemoradiation Trial Using Gemcitabine in Patients With Locoregional Adenocarcinoma of the Pancreas
Status: Enrolling
Updated:  7/19/2016
CCOP - Southeast Cancer Control Consortium
305
mi
from 43215
Winston-Salem, NC
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
Phase II Chemoradiation Trial Using Gemcitabine in Patients With Locoregional Adenocarcinoma of the Pancreas
Status: Enrolling
Updated: 7/19/2016
CCOP - Southeast Cancer Control Consortium
305
mi
from 43215
Winston-Salem, NC
Click here to add this to my saved trials
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
Phase II Chemoradiation Trial Using Gemcitabine in Patients With Locoregional Adenocarcinoma of the Pancreas
Status: Enrolling
Updated:  7/19/2016
Comprehensive Cancer Center of Wake Forest University Baptist Medical Center
306
mi
from 43215
Winston-Salem, NC
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
Phase II Chemoradiation Trial Using Gemcitabine in Patients With Locoregional Adenocarcinoma of the Pancreas
Status: Enrolling
Updated: 7/19/2016
Comprehensive Cancer Center of Wake Forest University Baptist Medical Center
306
mi
from 43215
Winston-Salem, NC
Click here to add this to my saved trials
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
Phase II Chemoradiation Trial Using Gemcitabine in Patients With Locoregional Adenocarcinoma of the Pancreas
Status: Enrolling
Updated:  7/19/2016
Arthur G. James Cancer Hospital - Ohio State University
2
mi
from 43215
Columbus, OH
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
Phase II Chemoradiation Trial Using Gemcitabine in Patients With Locoregional Adenocarcinoma of the Pancreas
Status: Enrolling
Updated: 7/19/2016
Arthur G. James Cancer Hospital - Ohio State University
2
mi
from 43215
Columbus, OH
Click here to add this to my saved trials
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
Phase II Chemoradiation Trial Using Gemcitabine in Patients With Locoregional Adenocarcinoma of the Pancreas
Status: Enrolling
Updated:  7/19/2016
Rhode Island Hospital
619
mi
from 43215
Providence, RI
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
Phase II Chemoradiation Trial Using Gemcitabine in Patients With Locoregional Adenocarcinoma of the Pancreas
Status: Enrolling
Updated: 7/19/2016
Rhode Island Hospital
619
mi
from 43215
Providence, RI
Click here to add this to my saved trials
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
Phase II Chemoradiation Trial Using Gemcitabine in Patients With Locoregional Adenocarcinoma of the Pancreas
Status: Enrolling
Updated:  7/19/2016
Medical University of South Carolina
524
mi
from 43215
Charleston, SC
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
Phase II Chemoradiation Trial Using Gemcitabine in Patients With Locoregional Adenocarcinoma of the Pancreas
Status: Enrolling
Updated: 7/19/2016
Medical University of South Carolina
524
mi
from 43215
Charleston, SC
Click here to add this to my saved trials
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
Phase II Chemoradiation Trial Using Gemcitabine in Patients With Locoregional Adenocarcinoma of the Pancreas
Status: Enrolling
Updated:  7/19/2016
Veterans Affairs Medical Center - Memphis
507
mi
from 43215
Memphis, TN
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
Phase II Chemoradiation Trial Using Gemcitabine in Patients With Locoregional Adenocarcinoma of the Pancreas
Status: Enrolling
Updated: 7/19/2016
Veterans Affairs Medical Center - Memphis
507
mi
from 43215
Memphis, TN
Click here to add this to my saved trials
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
Phase II Chemoradiation Trial Using Gemcitabine in Patients With Locoregional Adenocarcinoma of the Pancreas
Status: Enrolling
Updated:  7/19/2016
University of Tennessee, Memphis Cancer Center
507
mi
from 43215
Memphis, TN
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
Phase II Chemoradiation Trial Using Gemcitabine in Patients With Locoregional Adenocarcinoma of the Pancreas
Status: Enrolling
Updated: 7/19/2016
University of Tennessee, Memphis Cancer Center
507
mi
from 43215
Memphis, TN
Click here to add this to my saved trials
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
Phase II Chemoradiation Trial Using Gemcitabine in Patients With Locoregional Adenocarcinoma of the Pancreas
Status: Enrolling
Updated:  7/19/2016
Vermont Cancer Center
590
mi
from 43215
Burlington, VT
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
Phase II Chemoradiation Trial Using Gemcitabine in Patients With Locoregional Adenocarcinoma of the Pancreas
Status: Enrolling
Updated: 7/19/2016
Vermont Cancer Center
590
mi
from 43215
Burlington, VT
Click here to add this to my saved trials
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
Phase II Chemoradiation Trial Using Gemcitabine in Patients With Locoregional Adenocarcinoma of the Pancreas
Status: Enrolling
Updated:  7/19/2016
Veterans Affairs Medical Center - White River Junction
606
mi
from 43215
White River Junction, VT
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
Phase II Chemoradiation Trial Using Gemcitabine in Patients With Locoregional Adenocarcinoma of the Pancreas
Status: Enrolling
Updated: 7/19/2016
Veterans Affairs Medical Center - White River Junction
606
mi
from 43215
White River Junction, VT
Click here to add this to my saved trials
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
Phase II Chemoradiation Trial Using Gemcitabine in Patients With Locoregional Adenocarcinoma of the Pancreas
Status: Enrolling
Updated:  7/19/2016
Veterans Affairs Medical Center - Richmond
342
mi
from 43215
Richmond, VA
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
Phase II Chemoradiation Trial Using Gemcitabine in Patients With Locoregional Adenocarcinoma of the Pancreas
Status: Enrolling
Updated: 7/19/2016
Veterans Affairs Medical Center - Richmond
342
mi
from 43215
Richmond, VA
Click here to add this to my saved trials
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
Phase II Chemoradiation Trial Using Gemcitabine in Patients With Locoregional Adenocarcinoma of the Pancreas
Status: Enrolling
Updated:  7/19/2016
MBCCOP - Massey Cancer Center
344
mi
from 43215
Richmond, VA
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
Phase II Chemoradiation Trial Using Gemcitabine in Patients With Locoregional Adenocarcinoma of the Pancreas
Status: Enrolling
Updated: 7/19/2016
MBCCOP - Massey Cancer Center
344
mi
from 43215
Richmond, VA
Click here to add this to my saved trials
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/19/2016
Veterans Affairs Medical Center - Birmingham
492
mi
from 43215
Birmingham, AL
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/19/2016
Veterans Affairs Medical Center - Birmingham
492
mi
from 43215
Birmingham, AL
Click here to add this to my saved trials
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/19/2016
University of California San Diego Cancer Center
1926
mi
from 43215
La Jolla, CA
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/19/2016
University of California San Diego Cancer Center
1926
mi
from 43215
La Jolla, CA
Click here to add this to my saved trials
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/19/2016
UCSF Cancer Center and Cancer Research Institute
2109
mi
from 43215
San Francisco, CA
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/19/2016
UCSF Cancer Center and Cancer Research Institute
2109
mi
from 43215
San Francisco, CA
Click here to add this to my saved trials
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/19/2016
Veterans Affairs Medical Center - San Francisco
2111
mi
from 43215
San Francisco, CA
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/19/2016
Veterans Affairs Medical Center - San Francisco
2111
mi
from 43215
San Francisco, CA
Click here to add this to my saved trials
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/19/2016
CCOP - Christiana Care Health Services
396
mi
from 43215
Wilmington, DE
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/19/2016
CCOP - Christiana Care Health Services
396
mi
from 43215
Wilmington, DE
Click here to add this to my saved trials
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/19/2016
Vincent T. Lombardi Cancer Research Center, Georgetown University
325
mi
from 43215
Washington,
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/19/2016
Vincent T. Lombardi Cancer Research Center, Georgetown University
325
mi
from 43215
Washington,
Click here to add this to my saved trials
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/19/2016
Walter Reed Army Medical Center
328
mi
from 43215
Washington,
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/19/2016
Walter Reed Army Medical Center
328
mi
from 43215
Washington,
Click here to add this to my saved trials
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/19/2016
Mount Sinai Medical Center CCOP
991
mi
from 43215
Miami Beach, FL
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/19/2016
Mount Sinai Medical Center CCOP
991
mi
from 43215
Miami Beach, FL
Click here to add this to my saved trials
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/19/2016
University of Illinois at Chicago Health Sciences Center
274
mi
from 43215
Chicago, IL
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/19/2016
University of Illinois at Chicago Health Sciences Center
274
mi
from 43215
Chicago, IL
Click here to add this to my saved trials
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/19/2016
Veterans Affairs Medical Center - Chicago Westside Hospital
277
mi
from 43215
Chicago, IL
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/19/2016
Veterans Affairs Medical Center - Chicago Westside Hospital
277
mi
from 43215
Chicago, IL
Click here to add this to my saved trials
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/19/2016
University of Chicago Cancer Research Center
270
mi
from 43215
Chicago, IL
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/19/2016
University of Chicago Cancer Research Center
270
mi
from 43215
Chicago, IL
Click here to add this to my saved trials
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/19/2016
University of Iowa Hospitals and Clinics
460
mi
from 43215
Iowa City, IA
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/19/2016
University of Iowa Hospitals and Clinics
460
mi
from 43215
Iowa City, IA
Click here to add this to my saved trials
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/19/2016
Veterans Affairs Medical Center - Togus
743
mi
from 43215
Togus, ME
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/19/2016
Veterans Affairs Medical Center - Togus
743
mi
from 43215
Togus, ME
Click here to add this to my saved trials
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/19/2016
Marlene & Stewart Greenebaum Cancer Center, University of Maryland
343
mi
from 43215
Baltimore, MD
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/19/2016
Marlene & Stewart Greenebaum Cancer Center, University of Maryland
343
mi
from 43215
Baltimore, MD
Click here to add this to my saved trials
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/19/2016
Massachusetts General Hospital Cancer Center
643
mi
from 43215
Boston, MA
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/19/2016
Massachusetts General Hospital Cancer Center
643
mi
from 43215
Boston, MA
Click here to add this to my saved trials
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/19/2016
Dana-Farber Cancer Institute
643
mi
from 43215
Boston, MA
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/19/2016
Dana-Farber Cancer Institute
643
mi
from 43215
Boston, MA
Click here to add this to my saved trials
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/19/2016
University of Massachusetts Memorial Medical Center
607
mi
from 43215
Worcester, MA
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/19/2016
University of Massachusetts Memorial Medical Center
607
mi
from 43215
Worcester, MA
Click here to add this to my saved trials
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/19/2016
Veterans Affairs Medical Center - Minneapolis
621
mi
from 43215
Minneapolis, MN
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/19/2016
Veterans Affairs Medical Center - Minneapolis
621
mi
from 43215
Minneapolis, MN
Click here to add this to my saved trials
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/19/2016
Veterans Affairs Medical Center - Columbia (Truman Memorial)
501
mi
from 43215
Columbia, MO
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/19/2016
Veterans Affairs Medical Center - Columbia (Truman Memorial)
501
mi
from 43215
Columbia, MO
Click here to add this to my saved trials
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/19/2016
Ellis Fischel Cancer Center - Columbia
501
mi
from 43215
Columbia, MO
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/19/2016
Ellis Fischel Cancer Center - Columbia
501
mi
from 43215
Columbia, MO
Click here to add this to my saved trials
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/19/2016
Barnes Jewish Hospital
397
mi
from 43215
Saint Louis, MO
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/19/2016
Barnes Jewish Hospital
397
mi
from 43215
Saint Louis, MO
Click here to add this to my saved trials
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/19/2016
Veterans Affairs Medical Center - Omaha
684
mi
from 43215
Omaha, NE
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/19/2016
Veterans Affairs Medical Center - Omaha
684
mi
from 43215
Omaha, NE
Click here to add this to my saved trials
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/19/2016
Univ of Nebraska Med Ctr
682
mi
from 43215
Omaha, NE
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/19/2016
Univ of Nebraska Med Ctr
682
mi
from 43215
Omaha, NE
Click here to add this to my saved trials
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/19/2016
CCOP - Southern Nevada Cancer Research Foundation
1757
mi
from 43215
Las Vegas, NV
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/19/2016
CCOP - Southern Nevada Cancer Research Foundation
1757
mi
from 43215
Las Vegas, NV
Click here to add this to my saved trials
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/19/2016
Norris Cotton Cancer Center
609
mi
from 43215
Lebanon, NH
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/19/2016
Norris Cotton Cancer Center
609
mi
from 43215
Lebanon, NH
Click here to add this to my saved trials
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/19/2016
Veterans Affairs Medical Center - Buffalo
299
mi
from 43215
Buffalo, NY
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/19/2016
Veterans Affairs Medical Center - Buffalo
299
mi
from 43215
Buffalo, NY
Click here to add this to my saved trials
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/19/2016
Roswell Park Cancer Institute
295
mi
from 43215
Buffalo, NY
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/19/2016
Roswell Park Cancer Institute
295
mi
from 43215
Buffalo, NY
Click here to add this to my saved trials
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/19/2016
CCOP - North Shore University Hospital
493
mi
from 43215
Manhasset, NY
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/19/2016
CCOP - North Shore University Hospital
493
mi
from 43215
Manhasset, NY
Click here to add this to my saved trials
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/19/2016
North Shore University Hospital
493
mi
from 43215
Manhasset, NY
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/19/2016
North Shore University Hospital
493
mi
from 43215
Manhasset, NY
Click here to add this to my saved trials
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/19/2016
Memorial Sloan Kettering Cancer Center
480
mi
from 43215
New York, NY
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/19/2016
Memorial Sloan Kettering Cancer Center
480
mi
from 43215
New York, NY
Click here to add this to my saved trials
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/19/2016
The New York Presbyterian Hospital - Cornell Campus
480
mi
from 43215
New York, NY
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/19/2016
The New York Presbyterian Hospital - Cornell Campus
480
mi
from 43215
New York, NY
Click here to add this to my saved trials